Combining Cyclosporin with Chemotherapy Controls Intraocular Retinoblastoma without Requiring Radiation

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1499-1508

  Chan, Helen S L ^a,b   DeBoer, Gerrit ^c   Thiessen, Jake J ^d   Budning, Andrew ^a   Kingston, Judith E ^f   O'Brien, Joan M ^h   Koren, Gideon ^a   Giesbrecht, Esther ^a   Haddad, George ^a,b   Verjee, Zul ^a   Hungerford, John L ^g   Ling, Victor ^e   Gallie, Brenda L ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF LONDON   (United Kingdom)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOSPORIN; ENZYME INHIBITOR; TENIPOSIDE; VINCRISTINE;

AREA UNDER THE CURVE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; HUMAN; HYPOPHOSPHATEMIA; INFANT; NEWBORN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RETINA TUMOR; RETINOBLASTOMA; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; HYPOPHOSPHATEMIA; INFANT; INFANT, NEWBORN; RETINAL NEOPLASMS; RETINOBLASTOMA; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE; WEIGHT LOSS;

EID: 0030223029     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Abramson, D. H., Ellsworth, R. M., Tretter, P., Adams, K., and Kitchin, F. D. Simultaneous bilateral radiation for advanced bilateral retinoblastoma. Arch. Ophthalmol., 99: 1763-1766, 1981
2. McCormick, B., Ellsworth, R., Abramson, D., Haik, B., Tome, M., Grabowski, E., and LoSasso, T. Radiation therapy for retinoblastoma: comparison of results with lens-sparing versus lateral beam techniques. Int. J. Radiat. Oncol. Biol. Phys., 15: 567-574, 1988.
3. Shields, J. A., Parsons, H., Shields, C L., and Giblin, M. E. The role of cryotherapy in the management of retinoblastoma. Am. J. Ophthalmol., 108: 260-264, 1989.
4. Abramson, D. H. The focal treatment of retinoblastoma with emphasis on xenon arc photocoagulation. Acta Ophthalmol., 194 (Suppl.): 3-63, 1989.
5. Shields, C. L., Shields, J. A., De Potter, P., Minelli, S., Hernandez, C., Brady, L. W., and Cater, J R. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology, 100: 216-224, 1993.
6. Eng, C. Li, F. P., Abramson, D. H., Ellsworth, R. M., Wong, F. L., Goldman, M. B., Seddon, J., Tarbell, N., and Boice, J. D., Jr. Mortality from second tumors among long-term survivors of retinoblastoma. J. Natl. Cancer Inst., 85: 1121-1128, 1993.
7. Imhof, S. M., Hofman, P., and Tan, K. E. Quantification of lacrimal function after D-shaped field irradiation for retinoblastoma. Br. J. Ophthalmol., 77: 482-484, 1993.
8. White, L. Chemotherapy in retinoblastoma: current status and future directions. Am. J. Pediatr. Hematol Oncol., 13, 189-201, 1991.
9. Chan, H. S. L., Canton, M. D., and Gallie, B. L. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res., 9: 469-474, 1989.
10. Chan, H. S. L., Thorner, P. S., Haddad, G., and Gallie, B. L. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology, 98: 1425-1431, 1991
11. Chan, H. S. L., Thorner, P. S., Haddad, G., and Gallie, B L. Effect of chemotherapy on intraocular retinoblastoma. Int. J. Pediatr Hematol Oncol., 2: 269-281, 1995.
12. Gerlach, J. H., Endicott, J. A., Juranka, P. F., Henderson, G., Sarangi, F., Deuchars, K. L., and Ling, V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature (Lond.), 324: 485-489, 1986.
13. Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G. M., Taylor, C W., Miller, T. P., and Salmon, S. E Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol., 7: 415-424, 1989.
14. Bourhis, J., Bénard, J., Hartmann, O., Boccon-Gibod, L., Lemerle, J., and Riou, G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl. Cancer Inst., 81: 1401-1405, 1989.
15. Chan, H. S. L., Thorner, P. S., Haddad, G., and Ling, V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol., 8: 689-704, 1990
16. Chan, H. S. L., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H., and Ling, V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J Med., 325: 1608-1614, 1991.
17. Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. I., and Salmon, S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol., 9: 17-24, 1991.
18. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., and Fiere, D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79: 473-476, 1992.
19. Goasguen, J. E., Dossot, J. M., Fardel, O., Le Mee, F., Le Gall, E., Leblay, R., LePrise, P. Y., Chaperon, J., and Fauchet, R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood, 81: 2394-2398, 1993.
20. Slater, L. M., Sweet, P., Stupecky, M., Wetzel, M W., and Gupta, S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma Br. J. Cancer, 54: 235-238, 1986.
21. Georges, E., Sharom, F J., and Ling, V. Multidrug resistance and chemosensitization. therapeutic implications for cancer chemotherapy In: T. August, M. W. Anders, F. Murad, and A. Nies (eds.), Advances in Pharmacology, Vol. 21, pp.185-220. San Diego: Academic Press, 1990.
22. Lee, T. W., Yang, S. W., Kim, C. M., Hong, W. S., and Youn, D. H. Chemosensitization to adriamycin by cyclosporin A and verapamil in human retinoblastoma cell lines. J Korean Med. Sci., 8: 104-109, 1993.
23. Kasham-Sabet, M., Wang, W., and Scanlon, K. J. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J. Biol Chem., 265. 11285-11288, 1990.
24. Karnofsky, D. A. Problems and pitfalls in the evaluation of anticancer drugs. Cancer (Phila.), 18: 1517-1528, 1965.
25. Reese, A B., and Ellsworth, R. M. The evaluation and current concept of retinoblastoma therapy. Trans. Am. Acad. Ophthalmol. Otolaryngol. 67: 164-172, 1963.
26. Bedford, M. A., Bedotto, C., and Macfaul, P. A. Retinoblastoma A study of 139 cases. Br. J. Ophthalmol , 55: 19-27, 1971.
27. Rozencweig, M., Stagnet, M., Hansen, H H., Pinedo, H. M., McVie, J. G., Armand, J. P., Kenis, Y., Fox, B. W., Harrap, K., and Van Putten, L. M. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. Eur. J. Cancer Clin. Oncol., 21: 1005-1007, 1985.
28. Hryniuk, W M. The importance of dose intensity in the outcome of chemotherapy. Important Adv. Oncol , 121-141, 1988.
29. Longo, D. L., Duffey, P. L., DeVita, V. T., Jr., Wesley, M. N , Hubbard, S M., and Young, R. C. The calculation of actual or received dose intensity: a comparison of published methods. J. Clin Oncol., 9. 2042-2051, 1991
30. Long, D., Koren, G , and James, A. Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates? J. Pediatr., 111: 918-921, 1987.
31. Giesbrecht, E. E.. Soldin, S. J., and Wong, P. Y. A rapid, reliable high-performance liquid chromatographic micromethod for the measurement of cyclosporine in whole blood Ther. Drug Monit., 11: 332-336, 1989
32. D'Argenio, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed., 9: 115-134, 1979.
33. Boxenbaum, H. G., Riegelman, S., and Elashoff, R. M. Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm., 2: 123-148, 1974.
34. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
35. Lum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., and Sikic, B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol., 10: 1635-1642, 1992.
36. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I., Walker, S , Goodman, P., Bjarnason, G., DeAngelis, C., and Bunting, P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53: 4837-4842, 1993.
37. Bartlett, N. L., Lum, B. L., Fisher, G. A , Brophy, N. A., Ehsan, M. N., Halsey, J., and Sikic, B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 12: 835-842, 1994.
38. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
39. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
40. Schipper, J., Tan, K. E., and Van Peperzeel, H. A Treatment of retinoblastoma by precision megavoltage radiation therapy. Radiother. Oncol., 3: 117-132, 1985.
41. Sonneveld, P., Dune, B. G., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B., and Nooter, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, 340: 255-259, 1992.
42. List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., and Dalton, W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol., 11, 1652-1660, 1993.
43. Yahanda, A. M., Alder, K. M., Fisher, G. A., Brophy, N. A., Halsey, J.. Hardy, R. I., Gosland, M. P., Lum, B. L., and Sikic, B. I. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 10: 1624-1634, 1992.
44. Samuels, B. L., Mick, R., Vogelzang, N. J., Williams, S. F., Schilsky, R. L., Safa, A. R., O'Brien, S. M., and Ratain, M. J. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol. Ther., 54: 421-429, 1993.
45. Wilson, W. H., Bates, S. E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R. E., Jaffe, E S., Steinberg, S. M., Herdt, J., and Chabner, B. A. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol., 13: 1995-2004, 1995.
46. Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M. E , Planting, A. S., Seynaeve, C., Stoter, G., and Nooter, K. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br. J. Cancer, 64: 361-364, 1991.
47. Oh, C., Saville, B. A., Cheng, Y-L., and Rootman, D. S. A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits. Pharm. Res., 12: 433-437, 1995.
48. Morgan, R. J., Jr., Margolin, K., Raschko, J., Akman, S., Lcong, L , Somlo, G., Scanlon, K., Ahn, C., Carroll, M., and Doroshow, J. H. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J. Clin. Oncol., 13: 2238-2246, 1995.
49. Slater, L. M., Cho, J., and Wetzel, M. Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother. Pharmacol., 31: 53-56, 1992.
50. Horton, J. K., Thimmaiah, K. N , Houghton, J. A., Horowitz, M. E., and Houghton, P. J Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem. Pharmacol., 38: 1727-1736, 1989.
51. Schinkel, A. H., Smit, J. J. M., Van Tellingen, O., Beijnen, J. H., Wagenaar, E., Van Deemter, L., Mol, C. A. A. M., Van der Valk, M. A , Robanus-Maandag, E. C., Te Riele, H. P. J., Berns, A. J. M., and Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994
52. Cordon-Cardo, C., O'Bnen, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38: 1277-1287, 1990.
53. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattrunger, C, Huber, H., and Andreeff, M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood, 80: 2729-2734, 1992.
54. Gosland, M., Brophy, N. A , Duran, G. E., Yahanda, A. M., Adler, K. M., Hardy, R. I., Halsey, J., and Sikic, B. I Bilirubin: a physiological substrate for the multidrug resistance transporter. Proc. Am. Assoc. Cancer Res., 32: 426, 1991.
55. Yee, G. C., Lennon, T. P., Gmur, D J., Kennedy, M. S., and Deeg, H. J. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin. Pharmacol. Ther., 40: 438-443, 1986.
56. Draper, G. J., Sanders, B. M., and Kingston, J. E. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer, 53, 661-671, 1986.
57. Pui, C. H., Ribeiro, R. C., Hancock, M. L., Rivera, G. K., Evans, W. E., Raimondi, S. C., Head, D. R., Behm, F. G., Mahmoud, M. H., Sandlund, J. T., and Crist, W. M. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med., 325: 1682-1687, 1991.